{"address1": "2-5-1, Nihonbashi-Honcho", "address2": "Chuo-Ku", "city": "Tokyo", "zip": "103-8411", "country": "Japan", "phone": "81 3 3244 3000", "website": "https://www.astellas.com", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.", "fullTimeEmployees": 14484, "companyOfficers": [{"maxAge": 1, "name": "Mr. Naoki  Okamura BSc", "age": 61, "title": "President, CEO & Director", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 146000000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Atsushi  Kitamura", "title": "Chief Financial Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Nobue  Yasuda", "title": "General Manager of Finance & Accounting Department", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Yoshitsugu  Shitaka Ph.D.", "title": "Chief Scientific Officer & Senior Managing Executive Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Catherine B. Levitt", "title": "General Counsel", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Katsuyoshi  Sugita", "age": 56, "title": "Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stig  Ogata", "title": "Vice President of Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Collette  Taylor", "age": 60, "title": "Senior Vice President of Human Resources", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tatjana  Dragovic", "title": "Senior VP and Head of Ethics & Compliance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nobuaki  Tanaka", "title": "President of Japan Commercial & Senior Corporate Executive", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 1, "boardRisk": 2, "compensationRisk": 1, "shareHolderRightsRisk": 6, "overallRisk": 2, "governanceEpochDate": 1709251200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 1677.0, "open": 1669.0, "dayLow": 1651.5, "dayHigh": 1674.0, "regularMarketPreviousClose": 1677.0, "regularMarketOpen": 1669.0, "regularMarketDayLow": 1651.5, "regularMarketDayHigh": 1674.0, "dividendRate": 70.0, "dividendYield": 0.0417, "exDividendDate": 1711584000, "payoutRatio": 24.528301, "fiveYearAvgDividendYield": 2.62, "beta": 0.283, "trailingPE": 624.2537, "forwardPE": 19.469336, "volume": 2410000, "regularMarketVolume": 2410000, "averageVolume": 8303936, "averageVolume10days": 9521150, "averageDailyVolume10Day": 9521150, "bid": 1669.5, "ask": 1670.0, "marketCap": 2999672111104, "fiftyTwoWeekLow": 1551.0, "fiftyTwoWeekHigh": 2360.5, "priceToSalesTrailing12Months": 1.9436437, "fiftyDayAverage": 1675.3, "twoHundredDayAverage": 1919.435, "trailingAnnualDividendRate": 65.0, "trailingAnnualDividendYield": 0.03875969, "currency": "JPY", "enterpriseValue": 3594533208064, "profitMargins": 0.0027200002, "floatShares": 1792771265, "sharesOutstanding": 1792989952, "heldPercentInsiders": 0.00248, "heldPercentInstitutions": 0.52554, "impliedSharesOutstanding": 1792989952, "bookValue": 838.408, "priceToBook": 1.9954485, "lastFiscalYearEnd": 1680220800, "nextFiscalYearEnd": 1711843200, "mostRecentQuarter": 1703980800, "earningsQuarterlyGrowth": -0.7, "netIncomeToCommon": 4198000128, "trailingEps": 2.68, "forwardEps": 85.93, "pegRatio": 2.49, "lastSplitFactor": "5:1", "lastSplitDate": 1395878400, "enterpriseToRevenue": 2.329, "enterpriseToEbitda": 14.435, "52WeekChange": -0.106619656, "SandP52WeekChange": 0.32311738, "lastDividendValue": 35.0, "lastDividendDate": 1711584000, "exchange": "JPX", "quoteType": "EQUITY", "symbol": "4503.T", "underlyingSymbol": "4503.T", "shortName": "ASTELLAS PHARMA", "longName": "Astellas Pharma Inc.", "firstTradeDateEpochUtc": 946944000, "timeZoneFullName": "Asia/Tokyo", "timeZoneShortName": "JST", "uuid": "c4b57d38-3830-3837-b8a6-69dfd60c55b5", "messageBoardId": "finmb_874641", "gmtOffSetMilliseconds": 32400000, "currentPrice": 1673.0, "targetHighPrice": 3170.0, "targetLowPrice": 1500.0, "targetMeanPrice": 2165.4, "targetMedianPrice": 2100.0, "recommendationMean": 2.3, "recommendationKey": "buy", "numberOfAnalystOpinions": 13, "totalCash": 285435985920, "totalCashPerShare": 159.196, "ebitda": 249010995200, "totalDebt": 873131016192, "quickRatio": 0.686, "currentRatio": 0.91, "totalRevenue": 1543324041216, "debtToEquity": 58.083, "revenuePerShare": 858.628, "returnOnAssets": 0.024820002, "returnOnEquity": 0.00273, "freeCashflow": 58085498880, "operatingCashflow": 216089001984, "earningsGrowth": -0.691, "revenueGrowth": 0.049, "grossMargins": 0.81758004, "ebitdaMargins": 0.16135, "operatingMargins": 0.04472, "financialCurrency": "JPY", "trailingPegRatio": null}